This study is looking at whether a dietary supplement called Mitoquinone (MitoQ) can improve the health of brain arteries in postmenopausal women aged 60 or older. MitoQ is a special antioxidant that targets the mitochondria (the 'powerhouses' of your cells) to reduce something called mitochondrial reactive oxygen species (mitoROS), which can be linked to aging and menopause. Researchers want to see if taking MitoQ for three months can improve brain artery function and if it does so by lowering mitoROS. You would be compared to a placebo, which looks like MitoQ but contains no active ingredient. To join, you must be a postmenopausal woman, 60 years or older, not currently using hormone therapies, and have a BMI of 35 or less. The study aims to enroll 86 participants, but its current status is unclear.

Study design

This is an interventional study comparing Mitoquinone (MitoQ) to a placebo in 86 postmenopausal women. Participants will be randomly assigned to receive either MitoQ or the placebo.

What's involved

You would take either MitoQ or a placebo for 3 months. Your cerebrovascular conductance will be measured at 3 months.

Compensation

Not stated in the trial record.

Follow-up

Your cerebrovascular conductance will be measured at 3 months, which is the end of the study's primary endpoint.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.